- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05407792
Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis
Efficacy and Safety of Long-term Oral Administration of Staphylococcus Albicans Tablets in Patients With Acute Exacerbation and Stable Bronchiectasis: a Multicenter, Prospective Randomized Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250014
- Recruiting
- Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University
-
Contact:
- Qian Qi, Doctor
- Phone Number: +86 13706380314
- Email: qiqianqlh@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with bronchiectasis diagnosed by clinical manifestations and chest HRCT according to the diagnostic criteria for bronchiectasis;
Patients with idiopathic or post-infectious bronchiectasis;
18years old;
Patients should have at least 2 acute exacerbations within 1 year before enrollment;
- Patients in either acute exacerbation or stable period can be included.
Exclusion Criteria:
Cystic fibrosis;
Immunodeficiency, allergic bronchopulmonary aspergillosis, etc.;
Traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis;
Still smoking;
Complicated with asthma or chronic obstructive disease Lung;
Patients with severe cardiovascular disease, severe neurological disease, or severe liver or kidney damage;
Malignant tumors;
Allergy to Staphylococcus albicans tablets;
Patients with a history of gastric ulcer or intestinal malabsorption;
Pregnant or lactating women;
patients with poor compliance;
previous (within 6 months before the start of the study) or concurrently taking immunostimulating drugs (including thymosin, interferon, transfer factor, BCG, pneumonia vaccine and any kind of bacteria Extracts, such as Biostim, except for influenza vaccine) or immunosuppressants;
- Patients who are participating in or have participated in interventional clinical trials within 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
Oral staphylococcus albicans tablet group.
|
0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
Other Names:
|
Other: Control group
On-demand treatment group
|
At the time of enrollment, patients with acute exacerbation of bronchiectasis were given routine treatment.
For patients with stable bronchiectasis at the time of enrollment, they are treated as needed (that is, according to the needs of the disease, receive corresponding treatment).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of acute exacerbations
Time Frame: Up to 12 months
|
Up to 12 months
|
Time to first exacerbation
Time Frame: Up to 12 months
|
Up to 12 months
|
Rate of readmission at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Number of acute exacerbations
Time Frame: up to 6 months
|
up to 6 months
|
Number of acute exacerbations
Time Frame: Up to 3 months
|
Up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline Life Quality Score at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Change from Baseline FEV1 at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Change from Baseline FEV1/FVC at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Change from Baseline FEV1 % predicted at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Change from Baseline sputum volume at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Change from Baseline percentage of patients with yellow purulent sputum at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Change from Baseline percentage of patients with immune dysfunction at 12 months
Time Frame: Up to 12 months
|
Up to 12 months
|
Change from Baseline of percentage of patients with positive sputum culture
Time Frame: Up to 12 months
|
Up to 12 months
|
Number of Participants with adverse reactions
Time Frame: Up to 12 months
|
Up to 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-5-26-QFS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiectasis
-
Chang Gung Memorial HospitalNot yet recruitingBronchiectasis AdultTaiwan
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingBronchiectasis AdultChina
-
Ruijin HospitalAstraZeneca Investment (China) Co., LtdNot yet recruitingBronchiectasis AdultChina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Fondazione Policlinico Universitario Agostino Gemelli IRCCS; IRCCS Azienda... and other collaboratorsActive, not recruiting
-
University of Sao Paulo General HospitalEnrolling by invitation
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompletedBronchiectasis AdultBrazil
-
University of North Carolina, Chapel HillCompletedBronchiectasis AdultUnited States
-
Seoul National University Bundang HospitalUnknownSymptomatic BronchiectasisKorea, Republic of
-
Shanghai Pulmonary Hospital, Shanghai, ChinaNot yet recruitingBronchiectasis Adult
-
University of DundeeRecruitingBronchiectasis AdultUnited Kingdom
Clinical Trials on Staphylococcus and Neisseria Tablets
-
Peking University Third HospitalNot yet recruitingChronic Obstructive Pulmonary DiseaseChina
-
Jiangsu Province Centers for Disease Control and...Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.CompletedStaphylococcus Aureus InfectionChina
-
Centre Hospitalier Universitaire de NīmesPherecydes PharmaNot yet recruitingDiabetic Foot | Staphylococcal InfectionsFrance
-
University Hospital, Strasbourg, FranceNot yet recruitingChlamydia Trachomatis | Neisseria Gonorrhoeae | Uncomplicated Infections
-
University Hospital Southampton NHS Foundation...University of SouthamptonUnknownMeningitis, MeningococcalUnited Kingdom
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University of Southern CaliforniaUniversity of California, San Diego; Botswana Harvard AIDS Institute PartnershipCompletedPreterm Birth | Gonorrhea | Neonatal Infection | Chlamydia Trachomatis InfectionUnited States, Botswana
-
Jiangsu Province Centers for Disease Control and...Third Military Medical University; Chengdu Olymvax Biopharmaceuticals Inc.CompletedStaphylococcus Aureus InfectionChina
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Jiangsu Province Centers for Disease Control and...Chengdu Olymvax Biopharmaceuticals Inc.; PLA Army Medical UniversityCompletedStaphylococcus Aureus InfectionChina